Latest Therapeutics News

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

AVITA Medical reported a 21% revenue increase in Q2 2025 driven by expanded sales and new product launches, yet continues to face net losses and liquidity challenges requiring loan covenant waivers.

AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.

Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.

PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.

AVITA Medical reported a 21% increase in Q2 commercial revenue to $18.4 million and narrowed its net loss, yet faces a reimbursement hurdle that forced a downward revision of full-year guidance. The company highlights clinical progress and strategic board appointments as it navigates payment challenges.

Amplia Therapeutics reports encouraging interim results from its ACCENT trial, with its drug narmafotinib improving progression-free survival and response rates in advanced pancreatic cancer.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Race Oncology’s Phase 1b/2 trial of RC110 bisantrene for relapsed or refractory acute myeloid leukemia has demonstrated a 40% response rate, exceeding expectations and offering new hope for difficult-to-treat patients.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.